Trial intelligence / Profile preview

Phase II fruquintinib monotherapy as second-line treatment in unresectable advanced or recurrent colorectal cancer ineligible for standard chemotherapy

jRCTs041260017Phase 2Recruiting

Sponsor

Takeda

Start

Jun 2026

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1